Professionals >

Representative Engagements >

Since its enactment in 1984, the Hatch-Waxman Act has saved consumers, insurers, and government payers over $1 trillion by enabling generic pharmaceutical companies to bring to market less expensive alternatives to branded drug products more expeditiously via the ANDA, or Abbreviated New Drug Application, process. Crowell & Moring is committed to representing generic pharmaceutical clients in ANDA litigation arising under the Hatch-Waxman Act. Our experience and know-how make us uniquely qualified to handle all stages of ANDA litigation for first filers and subsequent filers alike, from initial pre-suit investigation, counseling through trial and appeal, "at-risk" launch, and settlement. Moreover, our understanding of the regulatory framework surrounding ANDA litigation and the interplay between district courts and FDA proceedings allows us to implement successful and creative legal and regulatory strategies on behalf of our clients.

Crowell & Moring's Intellectual Property Group includes first-chair trial lawyers with years of experience litigating ANDA cases on behalf of generic pharmaceutical clients, and numerous other attorneys with significant trial experience in ANDA litigation. The ANDA litigation team includes attorneys and non-attorney professionals with technical backgrounds in biology, biotechnology, chemistry, biochemistry, organic chemistry, inorganic chemistry, and chemical engineering, as well as other related disciplines, including individuals with advanced technical degrees and Ph.D.'s in these disciplines. This depth equips Crowell & Moring with the ability to understand the complicated technical issues that often arise in these cases, as well as to translate these concepts to litigation strategies and successfully try complex ANDA litigation cases. 

Crowell & Moring's lawyers are also experienced in handling appeals of these cases before the Federal Circuit and have won many Paragraph IV litigations at the district court and appellate court levels.

Crowell & Moring's ANDA litigation attorneys include thought leaders in the biosimilars (generic biologics) field who have written and spoken extensively regarding the 2009 Biosimilar Price Competition and Innovation Act (BPCIA) and trial lawyers who have litigated biotechnology cases. With this experience, and the knowledge we have gained litigating and counseling generic pharmaceutical clients under the Hatch-Waxman Act, we are poised to guide clients through the new regulatory and emerging litigation processes under the BPCIA to successfully launch and market lower-cost biologic products. 

View More

"Doing It That Way Is Natural . . . and Patentable," IP Insights (August 12, 2020). Contacts: Anne Elise Herold Li, Siri Rao, Suzanne Trivette
Client Alert/Newsletter
Chinese Biotech Researcher Pleads Guilty to Trade Secret Misappropriation (August 10, 2020). Authors: Molly A. Jones and Julia Milewski.
Publications
DOJ Step-by-Step Guidance to Determine if Trade Secrets are Confidential Under the Freedom of Information Act (FOIA) (July 29, 2020). Authors: John Arszulowicz and Astor Heaven.
Publications
"Belgian Supreme Court Rules: Creative Use of the Law is Insufficient Ground for Lawyers to Claim Copyright Protection on Work Product," IP Insights (July 27, 2020). Contacts: Jan-Diederik Lindemans, Ellen Desnyder
Client Alert/Newsletter
DOJ Targets Chinese Hackers for Stealing United States Trade Secrets (July 23, 2020). Authors: Siri Rao, Suzanne Trivette and Vincent J. Galluzzo.
Publications
Harvard Professor Indicted for Allegedly Lying About Participation in Chinese Talent Recruitment Program (July 20, 2020). Authors: Vincent J. Galluzzo, Siri Rao and Suzanne Trivette.
Publications
China Proposes Harsher Penalties for Trade Secret Theft in Draft Amendment (July 17, 2020). Authors: Molly A. Jones and Julia Milewski.
Publications
World Trademark Review Ranks Crowell & Moring in WTR 1000 (Jul.07.2020)
Firm News/Announcement
Surge Of Interest Expected For PTAB Fast-Track Program Law360 (July 7, 2020)
Media Mentions
"U.S. Patent Applicants Can Now Expedite Appeals Under New Pilot Program," IP Insights (July 6, 2020). Contacts: Deborah H. Yellin, Shannon Lentz
Client Alert/Newsletter

To view more News & Events for this area, please go to our desktop site.

Crowell & Moring LLP is an international law firm with more than 500 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, DC, New York, Los Angeles, San Francisco, Orange County, London, and Brussels.

View Desktop Site | Mobile Sitemap

Contact | Subscribe | Terms of Use | Privacy Statement | Alumni

© Crowell & Moring LLP 2020
Attorney advertising - prior results do not guarantee a similar outcome.